Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ISRCTN |
Last refreshed on:
|
11 October 2021 |
Main ID: |
ISRCTN89012092 |
Date of registration:
|
15/08/2007 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Monitoring the efficacy and safety of artemether-lumefantrine and artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Niamtougou, Sokode (Region Centrale) and Lome (Lome Commune) sentinels sites in Togo in 2007
|
Scientific title:
|
Monitoring the efficacy and safety of artemether-lumefantrine and artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Niamtougou, Sokode (Region Centrale) and Lome (Lome Commune) sentinels sites in Togo in 2007 |
Date of first enrolment:
|
01/07/2007 |
Target sample size:
|
450 |
Recruitment status: |
Completed |
URL:
|
https://www.isrctn.com/ISRCTN89012092 |
Study type:
|
Interventional |
Study design:
|
Randomised open two-arm controlled study (Treatment)
|
Phase:
|
Not Specified
|
|
Countries of recruitment
|
Switzerland
|
Togo
| | | | | | |
Contacts
|
Name:
|
Pascal
Ringwald |
Address:
|
World Health Organization
20 Avenue Appia
CH-1211
Geneva-27
Switzerland |
Telephone:
|
+41 (0)22 791 34 69 |
Email:
|
ringwaldp@who.int |
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Children aged 6 to 59 months old 2. Infection with Plasmodium falciparum 3. Parasitaemia, 2000 - 200 000 asexual forms per µl 4. Axillary temperature of 37.5°C or oral/rectal temperature of 38°C 5. Ability to swallow oral medication 6. Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule 7. Informed consent from the patient or from a parent or guardian in case of children
Exclusion criteria: 1. Presence of general danger signs among children less than 5 years old or other signs of severe and complicated falciparum malaria according to current WHO definitions 2. Mixed or mono-infection with another Plasmodium species 3. Presence of severe malnutrition (defined as a child whose weight-for-height is below -3 standard deviation or less than 70% of the median of the National Center for Health Statistics (NCHS)/WHO normalised reference values, or who has symmetrical oedema involving at least the feet or who has a Mid Upper Arm Circumference [MUAC] less than 110 mm) 4. Presence of febrile conditions due to diseases other than malaria (measles, acute lower tract respiratory infection, severe diarrhoea with dehydration, etc.), or other known underlying chronic or severe diseases (e.g. cardiac, renal, hepatic diseases, Human Immunodeficiency Virus [HIV]/Acquired Immune Deficiency Syndrom [AIDS]) 5. History of hypersensitivity reactions to any of the drug(s) being tested or used as alternative treatment
Age minimum:
Age maximum:
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Malaria Infections and Infestations Malaria
|
Intervention(s)
|
Patients will receive both of the following: 1. Artemether-lumefantrine: six doses over three days per os according to manufacturer recommendation 2. Artesunate 4 mg/kg/day for three days per os and amodiaquine 10 mg/kg/day for three days per os
Joint Sponsor: The World Health Organisation Regional Office for Africa (WHO AFRO) Cite du Djoue P.O. Box 06 Brazzaville Congo http://www.afro.who.int/malaria/
Principal Investigator: Dr Monique Dorkenoo-Agbeko 143, rue Malfakassa Sito-Aeroport Lome BP 7941 Lome 7829 Togo Tel: + 228 (0)221 38 01 154 Email: monicadork@yahoo.fr
|
Primary Outcome(s)
|
Adequate clinical and parasitological response Polymerase Chain Reaction (PCR) corrected at day 28.
|
Secondary Outcome(s)
|
Prevalence of adverse events.
|
Source(s) of Monetary Support
|
World Health Organization (WHO) (Switzerland), The World Health Organization Regional Office for Africa (WHO AFRO) (Togo)
|
Ethics review
|
Status:
Approval date:
Contact:
Ethics approval received from:
1. Ministere de la Sante du Togo on the 7th March 2007 (ref: 0109/2007/MS/CAB)
2. Ethics Review Committee of the World Health Organization (WHO) on the 11th June 2007 (ref: RPC221)
|
Results
|
Results available:
|
Yes |
Date Posted:
|
|
Date Completed:
|
31/10/2007 |
URL:
|
|
|
|